The final session of the first half opens with the S&P 500 grinding within striking distance of recent highs and a hawkish Federal Reserve in the background. Chair Kevin Warsh's June 17 FOMC meeting left rates at 3.50%–3.75% and removed the easing bias, and CME FedWatch shows roughly an 80% probability of zero cuts in 2026. Monday's analyst tape was unusually active, with fresh upgrades clustered in software, consumer, media, biotech, and communications infrastructure. The five names below all carry concrete upgrade or initiation actions from June 26 or June 29.
AppLovin (APP) — Raymond James starts the name at Strong Buy
AppLovin is a mobile app advertising and software platform whose AXON engine helps developers and brands target and monetize users across mobile and connected TV. On June 29, Raymond James initiated coverage with a Strong Buy rating and a $640 price target, citing a long-term growth opportunity tied to AppLovin's machine-learning ad targeting and expansion into e-commerce advertising. The initiation lands alongside a deep bench of bulls, including Jefferies at Buy with $860, Morgan Stanley at Overweight with $800, Macquarie at Outperform with $730, and Wedbush at Outperform with $725.
Shares traded at $495.73 in the June 29 session, up 3.91%, with a market cap of $166.5 billion and a trailing P/E of 43. The 52-week range runs from $325.58 to $745.61. The consensus rating is Strong Buy, with 15 of 17 covering analysts bullish, an average target of $692.71, a median of $700, a high of $860, and a low of $515. The setup is a high-multiple growth name where every active analyst has a target above the current share price.
Risks: ad-tech multiples remain sensitive to digital ad spend cycles, mobile gaming attach rates can roll over quickly, regulatory scrutiny of mobile-app targeting is rising, and the gap between high and low targets implies meaningful disagreement on terminal growth.
Casey's General Stores (CASY) — BMO turns constructive after investor day
Casey's General Stores operates one of the largest convenience-store and pizza networks in the U.S. Midwest. On June 29, BMO Capital analyst Kelly Bania upgraded the stock from Market Perform to Outperform with a $950 target, following management meetings around the company's June 24 New York investor day. The upgrade complements a constructive sell-side panel including BNP Paribas at Outperform with $995, Wells Fargo at Overweight with $745, Evercore ISI at Outperform with $765, plus Jefferies and Stephens at Buy or Overweight. Goldman Sachs sits on the other side at Neutral with $795.
Shares closed at $780.71 on June 29, up 0.27%, with a market cap of $28.9 billion and a trailing P/E of 40.75. The 52-week range is $490 to $927.85. The consensus is Buy, with 7 of 11 analysts bullish, an average target of $924.55, a median of $960, a high of $995, and a low of $780. The editorial framing is a defensive growth compounder with national rollup optionality.
Risks: gasoline margin volatility remains a swing factor, prepared-food cost inflation could pressure store-level margins, integration of recent acquisitions adds execution risk, and the valuation already prices in continued double-digit unit growth.
Warner Bros. Discovery (WBD) — Seaport plays the deal closure
Warner Bros. Discovery owns the Max streaming service and the Warner Bros. film and television studios. On June 29, Seaport upgraded the stock from Neutral to Buy as a tactical play on the pending all-cash acquisition by Paramount Skydance at $31 per share, arguing that risks to deal closure are waning and the spread offers roughly 16% upside to the headline deal value. Existing bulls include Benchmark's Matthew Harrigan at Buy with $25 and Barrington's James Goss at Outperform with $25.
Shares traded at $27.10 on June 29, up 1.35%, with a market cap of $67.9 billion. The 52-week range is $10.76 to $30. The consensus is Buy, with 4 of 12 analysts bullish, an average target of $25.15, a median of $25.50, a high of $32, and a low of $13. The setup is best read as a merger arbitrage trade: the upside is the $31 cash consideration if the deal closes, with downside exposure to the standalone WBD valuation if it does not.
Risks: antitrust or regulatory review could delay or block the deal, Max streaming losses remain a drag on standalone fundamentals, linear network revenue continues to decline, and any change in deal price or structure would reset the arbitrage.
Cytokinetics (CYTK) — UBS doubles its price target
Cytokinetics is a clinical-stage biopharma focused on muscle activator and inhibitor drugs, with aficamten as its lead program for hypertrophic cardiomyopathy. On June 29, UBS analyst Ashwani Verma upgraded the stock from Neutral to Buy and raised the price target from $69 to $115, citing upcoming earnings updates as catalysts and arguing the company is positioned for long-term value creation. Mizuho's Salim Syed has carried Outperform at $118 since June 24, Needham's Serge Belanger is at Buy with $102, and RBC, JP Morgan, and Morgan Stanley all sit at Outperform or Overweight.
Shares closed at $85.87 on June 29, up 4.47%, with a market cap of $10.7 billion. As a clinical-stage company, Cytokinetics does not yet have a meaningful trailing P/E. The 52-week range is $32.66 to $86.69, with shares pressing the upper end. The consensus is Strong Buy, with 18 of 19 analysts bullish, an average target of $98.68, a median of $97, a high of $140, and a low of $56.
Risks: aficamten's commercial trajectory still depends on regulatory approval timing and label, competing therapies are advancing in the same indication, the company remains pre-profitability with cash-burn sensitivity, and a single trial readout could move shares sharply in either direction.
American Tower (AMT) — RBC makes the tower stock a top idea
American Tower owns and operates one of the world's largest portfolios of communications sites, including macro cell towers and the CoreSite data-center business. On June 26, RBC Capital analyst Jonathan Atkin upgraded the stock from Sector Perform to Outperform and raised the price target from $195 to $205, naming it a new top idea on superior organic revenue growth versus tower peers and improving trends at CoreSite. The note matters because the same analyst had previously been neutral. Existing bulls include JP Morgan's Richard Choe at Overweight with $245, Citigroup's Michael Rollins at Buy with $225, and Morgan Stanley's Simon Flannery at Overweight with $235.
Shares traded at $167.69 on June 29, down 4.50% on the session, with a market cap of $78.1 billion, a trailing P/E of 18.69, and a dividend yield near 4%. The 52-week range is $165.08 to $234.33. The consensus is Strong Buy, with 12 of 14 analysts bullish, an average target of $217.64, a median of $213, a high of $260, and a low of $185. The setup is a high-yield infrastructure REIT trading at the bottom of its 52-week range right as a previously cautious analyst flips bullish.
Risks: higher-for-longer rates remain a headwind for REIT valuations broadly, carrier capex budgets are watched closely for any near-term softness, foreign exchange exposure is material given the international tower footprint, and CoreSite execution remains a key variable in the multiple-expansion thesis.
Found this helpful? Share it with others.